Antigen-specific T cells are the main effector cells in fighting and killing cancer cells. Some strategies using engineering cancer cells to stimulate immune responses to recognize cancer cells themselves have been developed. Creative Biolabs has a well-established platform and provides you with engineering cancer cell line services according to your requirements.

Engineering Cancer Cells for Cancer Therapy

Finding tumor-specific antigens and neoantigens is only one of the many challenges involved in early cell therapy discovery. The whole-tumor-cell vaccines offer a distinct advantage in that they express complete tumor-associated antigens and elicit robust immune responses. The whole tumor cells used as cancer vaccines are emerging as a transformable approach for personalized immunotherapy, although their therapeutic efficacy remains unsatisfying in patients with cancer.

• Engineering cancer cells with cytokines activate antitumor immune cell trafficking and antigen-specific T-cell activation signaling.
• This strategy addresses the lack of universally expressed tumor antigens and the risk of immune escape with treatments that target single antigens.

VEGF-C/VEGFR3 Pathway

Vascular endothelial growth factor-C (VEGF-C) and VEGF-D were the first specific lymphangiogenesis factors identified. Lymphangiogenesis has always been controversial in promoting and suppressing cancer. On the one hand, the VEGFC / VEGFR3 pathway signaling is a major molecular driver of lymphangiogenesis and has mainly been associated with the metastatic process in tumors. However, on the other hand, lymphangiogenesis promotes immune recognition and supports the recruitment and local priming of naïve T cells. Researchers are seeking to develop a translational strategy that could exploit the lymphangiogenic potentiation of immune responses while avoiding the prometastatic aspects of tumor lymphangiogenesis.

VEGF-C key functions

• Angiogenesis
• Lymphangiogenesis
• Increasing lymphatic secretion of CCL21

Fig.1 A new cancer vaccine stimulates local lymphatic vessel growth and generates an anti-tumor response. (Wilson & Lund, 2021)

Engineering Cancer Cells with VEGFC Overexpression Service

Some studies showed that melanoma cells from mice engineered with VEGFC overexpression induced tumor lymphangiogenesis thus promoting T-cell infiltration and potentiating immunotherapy in melanoma. From this, we consider that lymphangiogenesis induction is a potential strategy as a novel immunotherapy. At Creative Biolabs, we develop genetically modified cancer cells with VEGFC overexpression to increase the killing of cancer cells by stimulating the immune system. Other than VEGFC overexpression, we also can engineer cancer cells with other cytokines and regulators overexpression.

Our cancer cell engineering services cover a range of different cell lines, including:

Creative Biolabs provides engineering cancer cell services to help our customers improve efficiency and expedite research. If you are interested in our services or have any specific needs, please feel free to contact us.

Reference

1. Wilson, J.T.; Lund, A.W. Building new roads to stronger immunity. Science Advances. 2021, 7(13): eabh3971.

For Research Use Only | Not For Clinical Use